Upon ingestion, the new Enzian dosage form resides in the stomach for several hours and steadily delivers drug into the blood. This enables enhanced effectiveness of many life-saving drug therapies.
The MarketWatch News Department was not involved in the creation of this content. MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and ...
A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold ...
The pharmaceutical sector is at a critical turning point as it becomes increasingly clear that even the most powerful cancer treatments depend on how effectively they reach tumors in therapeutic ...
Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence for drug design, announced today that it has secured the #1 global ranking for new U.S. patent families in AI Drug Discovery ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF ...
Gastroretentive drug delivery systems (GRDDS) represent a sophisticated approach to oral medication by extending the retention time of dosage forms in the stomach. This increased residence time can ...
FeSSIF pH of 5, bile salt; 15 mM of bile salt and 3.75 mM of lecithin FaSSIF-V2 pH of 6.5; 3 mM of bile salt and 0.2 mM of lecithin [32–36] FeSSIF-V2 pH 5.8; 10 mM of bile salt; 2 mM of lecithin and ...
MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (GELS) (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results